Department of General, Visceral and Pediatric Surgery, University Medical Center, Georg August University, Göttingen, Germany.
Digestion. 2022;103(4):245-252. doi: 10.1159/000524022. Epub 2022 Apr 7.
Liver metastases (LM) occur in about 50% of patients with colorectal cancer. Besides the multimodal treatment of the primary tumor, the only way to cure patients with colorectal LM (CRLM) is complete resection. Different surgical procedures for this purpose are available depending on location, size, and number of LM. Additional concepts for patients with primary unresectable LM exist, ranging from Chemotherapy to induction of liver hypertrophy and even liver transplantation. This review intends to provide an overview of the surgical approach.
Surgical options in the treatment of CRLM are defined and limited by their intraparenchymal location and their proximity to major vessels and intrahepatic bile ducts. Lesions located in the periphery can be excised in a parenchymal sparing fashion with a small tumor-surrounding resection margin of healthy liver parenchyma. If this is not possible, anatomical resections based on segmental boundaries are performed. In these cases, a sufficient functional volume of liver parenchyma after resection (future liver remnant volume [FLRV]) has to be preserved. This FLRV depends on various factors such as bodyweight and possible preexisting liver damage, such as cirrhosis, fibrosis, or chemotherapy-induced liver impairment. Liver hypertrophy via partial occlusion of the portal venous system is a standard procedure for patients with primary unresectable LM to increase FLRV. Furthermore, discussion of liver transplantation in cases of unresectable LM is gaining importance again. A combination of surgery and adjuvant and/or neoadjuvant chemotherapy may be indicated in individual cases, but general evidence-based recommendations cannot be given without further studies.
Surgical removal of all metastases represents the only option of a potentially curative treatment of UICC stage IV colorectal carcinoma with liver involvement. An interdisciplinary approach consisting of chemotherapeutical downsizing and hypertrophy of the FLRV offers potential curative treatment for patients with initially unresectable metastases. For all others, liver transplantation is seeing a revival showing promising results in overall survival compared to chemotherapy alone.
大约 50%的结直肠癌患者会发生肝转移(LM)。除了对原发性肿瘤进行多模式治疗外,治愈结直肠癌伴肝转移(CRLM)患者的唯一方法是完全切除。针对这种情况,有不同的手术程序可供选择,具体取决于 LM 的位置、大小和数量。对于原发性不可切除 LM 的患者,还存在其他治疗方案,从化疗到诱导肝肥大甚至肝移植。本综述旨在提供对手术方法的概述。
治疗 CRLM 的手术选择取决于其在肝内的位置及其与主要血管和肝内胆管的接近程度。位于边缘的病变可以以保留小块肝组织的方式进行切除,切除边缘只需保留少量健康肝组织。如果这不可行,则根据节段边界进行解剖性切除。在这些情况下,需要保留足够的术后剩余肝实质(未来肝体积 [FLRV])。这个 FLRV 取决于体重和可能存在的预先存在的肝损伤等各种因素,如肝硬化、纤维化或化疗引起的肝损伤。通过部分阻断门静脉系统来增加肝体积是治疗原发性不可切除 LM 患者以增加 FLRV 的标准程序。此外,不可切除 LM 患者再次进行肝移植的讨论也变得越来越重要。在某些情况下,可能需要手术以及辅助和/或新辅助化疗的联合治疗,但在没有进一步研究的情况下,无法给出一般的基于证据的建议。
外科切除所有转移灶是治疗合并肝转移的 UICC 分期 IV 结直肠癌的唯一潜在治愈性方法。由化疗缩小肿瘤和增加 FLRV 组成的多学科方法为初始不可切除转移灶患者提供了潜在的治愈性治疗。对于其他所有人,肝移植正在复兴,与单独化疗相比,在总生存率方面显示出有希望的结果。